Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed Stocktwits - Wed Dec 18, 10:02AM CST

Viking’s own promising oral GLP-1 candidate, VK2735, is currently being studied for obesity and other metabolic conditions.

VKTX : 38.28 (-18.03%)
MRK : 98.34 (-1.72%)
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance Zacks Investment Research - Wed Dec 18, 10:02AM CST

Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...

AZN : 64.64 (-3.78%)
MRK : 98.34 (-1.72%)
PFE : 25.89 (-2.04%)
SNY : 47.01 (-3.94%)
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over Motley Fool - Thu Dec 12, 1:23PM CST

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare...

ALK : 62.44 (-1.20%)
MRK : 98.34 (-1.72%)
JNJ : 144.75 (-1.13%)
NKE : 76.90 (-1.41%)
$DOWI : 42,326.87 (-2.58%)
AMGN : 258.78 (-2.70%)
BA : 172.62 (-0.24%)
Buy enter button by Ardasavasciogullari via iStock
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy” Barchart - Wed Dec 11, 12:47PM CST

These two biotech companies look poised to deliver in the coming year.

PCVX : 85.75 (-4.57%)
$SPX : 5,872.16 (-2.95%)
MRK : 98.34 (-1.72%)
AIT : 244.46 (-3.87%)
PFE : 25.89 (-2.04%)
Top Analyst Reports for Alphabet, Oracle & Merck
Top Analyst Reports for Alphabet, Oracle & Merck Zacks Investment Research - Tue Dec 10, 3:46PM CST

Tuesday, December 10, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc....

GOOGL : 188.40 (-3.59%)
WFC : 68.76 (-2.90%)
MS : 121.04 (-5.25%)
MRK : 98.34 (-1.72%)
ORCL : 165.41 (-2.53%)
SCCO : 92.96 (-3.91%)
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC Zacks Investment Research - Tue Dec 10, 9:54AM CST

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation (BTD) to their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd),...

AZN : 64.64 (-3.78%)
MRK : 98.34 (-1.72%)
PFE : 25.89 (-2.04%)
2 Healthcare Dividend Stocks to Hold for the Long Haul Motley Fool - Sat Dec 7, 8:17AM CST

Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed...

MRK : 98.34 (-1.72%)
MDT : 80.03 (-1.65%)
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday Motley Fool - Fri Dec 6, 6:09PM CST

Summit Therapeutics (NASDAQ: SMMT) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors...

SMMT : 16.98 (-8.56%)
MRK : 98.34 (-1.72%)
JEF : 75.76 (-4.33%)
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ Zacks Investment Research - Fri Dec 6, 8:18AM CST

This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s...

AZN : 64.64 (-3.78%)
JNJ : 144.75 (-1.13%)
MRK : 98.34 (-1.72%)
LLY : 764.71 (-1.79%)
RHHBY : 34.9100 (-2.59%)
Merck & Co Inc billboard-by monticello via Shutterstock
How Is Merck's Stock Performance Compared to Other Pharmaceuticals Stocks? Barchart - Fri Dec 6, 6:12AM CST

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

MRK : 98.34 (-1.72%)
PJP : 82.44 (-2.54%)
LLY : 764.71 (-1.79%)

Barchart Exclusives

2 Dividend Stocks Analysts Love for Fat Yields in 2025 Barchart - Wed Dec 18, 6:30PM CST
These companies have high yields and have strong business models that position them to maintain and potentially increase their dividend payments in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot